Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
about
Nedaplatin: a cisplatin derivative in cancer chemotherapyImmunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational researchHuman Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical CancerPharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerationsA phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group studySystematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.A call for specific geriatric data on cervical cancers.Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204.Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.Major clinical research advances in gynecologic cancer 2009.Improved survival with bevacizumab in advanced cervical cancerAttenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.Down-Regulation of MicroRNA-210 Confers Sensitivity towards 1'S-1'-Acetoxychavicol Acetate (ACA) in Cervical Cancer Cells by Targeting SMAD4Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries.Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literaturePemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience.Targeting angiogenesis in advanced cervical cancer.Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancerNew molecular targets against cervical cancer.Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.
P2860
Q24623561-0A501CAF-68E7-4B33-ACBA-B166E5D48D60Q26744094-A43C92D7-DD8C-4708-B912-C34BFDC8DF64Q26799484-8AFB149F-7972-49E0-AC6F-3CBAEB0BA143Q28086919-5876D1F0-7B2E-477A-BC5C-36A4FCBEF674Q30275176-7605C393-03B5-4EA2-93DA-0F3D2E02EF39Q30354788-F7349214-B265-461B-9060-9B84B8B2858FQ30361969-75A139CE-5005-4C48-8E22-011AA372B922Q30371410-02DE6FC9-231E-4B06-B421-6224893A9B0BQ30491531-C6B36E2E-77E9-4D2F-82BB-CE7AF1AB6EDCQ30538743-70F68EDE-23CB-418A-AAB6-968BCF7DD9E5Q30538788-BFD80D81-85F2-4215-B893-C1CBCC4F465DQ31054769-3DAE2974-96E4-4CBE-BFB6-0F5424549419Q32187309-1815698E-2AD1-4ECF-80A1-F84D80367FD3Q33386149-7AF6E56E-C7F9-42FD-809D-90EE7ABDD511Q33406474-7353DF81-F530-4D28-9F70-6A42006CB281Q33406863-C33326AF-56BD-4B82-A015-E767978AB4B4Q33407093-BDF17125-3FF0-4D1D-AB20-FD5AD90FC91DQ33418750-55513100-E4C4-4619-8B69-E5BD9A36EBF2Q33431951-E20932F6-90B4-4FFE-8EDD-7AF2D47D9C8AQ33435722-B08D1BCB-DCD5-459E-B9C0-2AF30DF72478Q33441115-42738CB8-AA14-49A8-987E-B191F9D0571CQ33560967-AB976C85-44E4-47D6-8B51-8FA4703D93EBQ33566222-89A1F9F1-9367-44BD-B35C-60844306B180Q33633839-AE3376CD-7846-412E-A343-432CC2E1F061Q33653575-D344301D-50E5-4A7E-A5E6-BC59D22E038CQ33654659-59789232-10E2-4BBE-81B8-473D7BA58DD3Q33757149-C7AB23D1-28D3-4D16-9CAD-FC51B6F2BC18Q33859790-794B1DCC-E6DC-43F3-86FE-88327E7FF83AQ33908553-93B9C44D-0F53-4FBA-BD44-0B7C72BC6D72Q33917356-96B09040-354C-4870-B791-CF7F422D6087Q33955742-66FD658C-D6C9-4C37-A53E-3A8028827498Q34091240-A6FCB092-29F7-416B-94A8-A804CF33EDCAQ34142430-630D8842-E562-4104-ACE4-94AE6CB8DF88Q34328838-81406A72-6F73-4803-A8AC-BAA69A7026C8Q34389368-3F461639-42E5-449B-AC67-63A119F904C7Q34415906-890205D7-6117-4916-8B12-5916D1DD9D23Q34700859-41CB6D01-569D-4216-A238-BBAC6E122E1DQ34850394-0E0726F8-9AE8-4985-A4AF-FAA18CF74343Q34957243-02C389F7-685C-4A99-AA8B-FE97D9F44C1EQ35004744-3FDF0EA5-1E65-4AAB-844B-C91D4563C8C7
P2860
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase III trial of four cispla ...... ecologic Oncology Group study.
@ast
Phase III trial of four cispla ...... ecologic Oncology Group study.
@en
type
label
Phase III trial of four cispla ...... ecologic Oncology Group study.
@ast
Phase III trial of four cispla ...... ecologic Oncology Group study.
@en
prefLabel
Phase III trial of four cispla ...... ecologic Oncology Group study.
@ast
Phase III trial of four cispla ...... ecologic Oncology Group study.
@en
P2093
P2860
P356
P1476
Phase III trial of four cispla ...... ecologic Oncology Group study.
@en
P2093
Bradley J Monk
Cecelia H Boardman
D Scott McMeekin
David E Cohn
Lois M Ramondetta
Michael W Sill
P2860
P304
P356
10.1200/JCO.2009.21.8909
P407
P50
P577
2009-08-31T00:00:00Z